Embody and TrimRx describe online compounded GLP-1 pathways. Noom offers several medication plans with a digital behavior-change program. Their service menus and payment schedules differ.
Use the public offer details below to prepare questions. A licensed clinician should decide which treatment is appropriate; a listing order or sale price is not a clinical comparison.
Make the prices comparable
Identify the specific Noom pathway and its quarterly renewal, then obtain the current medicine-inclusive quotes from Embody and TrimRx. A microdose introductory rate should not be compared with a different standard-treatment invoice without explanation.
What each provider publicly describes
Embody: The fresh homepage displays semaglutide at $79 per month and tirzepatide at $129, alongside no-membership-fee language. Confirm the current treatment, amount supplied, renewal rate, and any promotional term before paying.
TrimRx: The official indexed homepage lists GLP-1 from $179 and GLP-1/GIP from $259. Confirm these starting figures at checkout, including the ongoing rate, amount supplied, and any promotional conditions. Other websites may quote different landing-page offers.
Noom Med: The pricing page describes several introductory offers followed by higher ongoing rates, frequently billed quarterly. Its branded-medication pathway advertises $39 to begin, then $129 per month after month one, billed quarterly, with medication charged separately. Some compounded pathways describe care, medication, and digital tools together.
Questions before choosing
Ask each service for the actual ingredients, route, amount supplied, dispensing pharmacy, first payment, ongoing payment, and commitment. Keep branded and compounded products distinct.
Confirm the clinical practice, how to contact the prescriber, refill assessment, and cancellation deadline. Marketing about results or convenience does not establish which provider is clinically superior.
Continue your comparison
Compare the GLP-1 programs, read the CoreAge Rx review, and use the program table to prepare questions about the complete offer.
Sources & offer details
Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.